Startups

Our startups

Be inspired. Search our startups.

Filter
Startups
2017  Finalist
Medical Devices

Nerves injured by trauma or surgery, including amputation, often cannot be repaired. Nerve fibers attempt to reconnect to their former targets, but instead produce a tangled, swollen, and inflamed neuroma - a source of debilitating pain for 20-30% of the 1.7M existing amputees, and the 185k new cases/year. No standard of care exists to prevent neuroma formation or treat them. We have created NervLok, a patent-pending bioengineered device that is placed onto the cut nerve-end to prevent neuroma.

2017  Finalist
Therapeutics (Pharma / Biotech)

Akanocure is developing a group of novel bio-inspired anti-cancer next generation small molecules (SGSM) that would have the affinities and elicit the protein-protein interaction modulation of macromolecules while retaining the high tumor permeability of small molecules. SGSM are designed to be inexpensive to develop, avoid the side effects of chemotherapy, elicit response in most patients, suppress metastasis and relapse, and could be synergistic when combined with immunotherapies.

2017  Finalist
Therapeutics (Pharma / Biotech)

ReviveMed is a precision-medicine platform that leverages the data from small molecules or metabolites. ReviveMed technology, which was developed at MIT and published in Nature Methods, uniquely overcomes the difficulty of using a large set of metabolomic data, and transform these data into actionable insight. Currently, we selected a few strategic clients from leading pharma/biotech companies to provide them with drug de-risking, biomarker discovery and therapeutic solutions.

2017  Finalist
Therapeutics (Pharma / Biotech)

Exciting discoveries in the life sciences often get stranded in tech transfer. That's where we discovered the research that enabled Nivien, a small molecule kinase inhibitor that we are developing to enhance the efficacy and lower the side effects of chemo and immunotherapy in treatment-resistant cancers. We are currently seeking capital to continue our ongoing preclinical trials for Investigational New Drug status in metastatic pancreatic adenocarcinoma.